Integrated Advisors Network LLC Has $422,000 Stake in AstraZeneca PLC (NASDAQ:AZN)

Integrated Advisors Network LLC reduced its position in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 85.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,447 shares of the company's stock after selling 37,163 shares during the period. Integrated Advisors Network LLC's holdings in AstraZeneca were worth $422,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Capital International Investors increased its stake in AstraZeneca by 1.9% during the 4th quarter. Capital International Investors now owns 37,507,159 shares of the company's stock worth $2,457,706,000 after acquiring an additional 686,008 shares during the period. Bank of America Corp DE increased its stake in AstraZeneca by 189.3% during the 4th quarter. Bank of America Corp DE now owns 24,026,966 shares of the company's stock worth $1,574,247,000 after acquiring an additional 15,722,197 shares during the period. Franklin Resources Inc. increased its stake in AstraZeneca by 1.9% during the 4th quarter. Franklin Resources Inc. now owns 19,480,569 shares of the company's stock worth $1,276,367,000 after acquiring an additional 357,894 shares during the period. Jennison Associates LLC increased its stake in AstraZeneca by 3.1% during the 4th quarter. Jennison Associates LLC now owns 15,430,963 shares of the company's stock worth $1,011,037,000 after acquiring an additional 466,416 shares during the period. Finally, Sanders Capital LLC increased its stake in AstraZeneca by 1.4% during the 4th quarter. Sanders Capital LLC now owns 15,186,692 shares of the company's stock worth $995,032,000 after acquiring an additional 212,301 shares during the period. 20.35% of the stock is owned by institutional investors and hedge funds.

AstraZeneca Price Performance

Shares of AZN traded up $1.95 during midday trading on Friday, hitting $72.82. The company's stock had a trading volume of 8,033,731 shares, compared to its average volume of 5,194,017. The company has a quick ratio of 0.74, a current ratio of 0.93 and a debt-to-equity ratio of 0.65. AstraZeneca PLC has a one year low of $61.24 and a one year high of $87.68. The stock has a market capitalization of $225.83 billion, a price-to-earnings ratio of 32.22, a price-to-earnings-growth ratio of 1.42 and a beta of 0.40. The company's fifty day simple moving average is $69.38 and its two-hundred day simple moving average is $69.67.

AstraZeneca (NASDAQ:AZN - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The company reported $1.24 earnings per share for the quarter, beating the consensus estimate of $1.10 by $0.14. AstraZeneca had a return on equity of 32.23% and a net margin of 13.01%. The company had revenue of $13.59 billion for the quarter, compared to the consensus estimate of $13.71 billion. During the same quarter last year, the business posted $2.06 EPS. AstraZeneca's revenue for the quarter was up 7.2% on a year-over-year basis. As a group, equities analysts expect that AstraZeneca PLC will post 4.51 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on AZN. Morgan Stanley began coverage on AstraZeneca in a research note on Wednesday, February 12th. They issued an "overweight" rating on the stock. UBS Group upgraded AstraZeneca from a "neutral" rating to a "buy" rating in a research note on Thursday, February 13th. Finally, BNP Paribas began coverage on AstraZeneca in a research note on Tuesday, April 15th. They issued an "outperform" rating and a $75.00 price target on the stock. One analyst has rated the stock with a hold rating, five have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, AstraZeneca currently has a consensus rating of "Buy" and a consensus target price of $85.00.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.